{{Drugbox
| IUPAC_name = naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
| image = NM-2201_structure.png

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Illegal in Sweden
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 837122-21-7
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 91864534
| ChemSpiderID      = 30922478
| smiles            = FCCCCCN1C=C(C(OC2=C(C=CC=C3)C3=CC=C2)=O)C4=CC=CC=C41
| StdInChI          = 1S/C24H22FNO2/c25-15-6-1-7-16-26-17-21(20-12-4-5-13-22(20)26)24(27)28-23-14-8-10-18-9-2-3-11-19(18)23/h2-5,8-14,17H,1,6-7,15-16H2
| StdInChIKey       = PRGFSQYZCKCBQO-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CCQ6IR3CU2

<!--Chemical data-->
| C=24 | H=22 | F=1 | N=1 | O=2
| molecular_weight = 375.4 g/mol
}}

'''NM-2201''' (also known as '''CBL-2201''') is an [[indole]]-based [[synthetic cannabinoid]] that presumably has similar properties to the closely related [[5F-PB-22]] and [[NNE1]], which are both [[full agonist]]s and [[Binding selectivity|unselectively]] bind to [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and [[Cannabinoid receptor type 2|CB<sub>2</sub>]] receptors with low nanomolar [[Affinity (pharmacology)#Protein-ligand binding|affinity]].<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0379073815003679 | title=CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate |author1=A.A. Kondrasenko |author2=E.V. Goncharov |author3=K.P. Dugaev |author4=A.I. Rubaylo | journal=Forensic Science International | date=December 2015 | volume=257 | pages=209–213 | doi=10.1016/j.forsciint.2015.08.023 | pmid=26386336}}</ref><ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/15334 | title=NM-2201 | publisher=Cayman Chemical | accessdate=9 July 2015}}</ref><ref>{{cite journal | url=https://link.springer.com/article/10.1007/s11419-015-0270-0 | title=Comprehensive review of the detection methods for synthetic cannabinoids and cathinones |author1=Akira Namera |author2=Maho Kawamura |author3=Akihiro Nakamoto |author4=Takeshi Saito |author5=Masataka Nagao | journal=Forensic Toxicology |date=March 2015  | doi=10.1007/s11419-015-0270-0 | volume=33 | pages=175–194}}</ref><ref>{{cite journal | url=http://www.fsijournal.org/article/S0379-0738(14)00395-8/abstract | title=Synthetic cannabinoids as designer drugs: New representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data |author1=V. Shevyrin |author2=V. Melkozerov |author3=A. Nevero |author4=O. Eltsov |author5=A. Baranovsky |author6=Yu. Shafran | journal=Forensic Science International | date=September  2014 | doi=10.1016/j.forsciint.2014.09.013 | volume=244 | pages=263–275 | pmid=25305529}}</ref>

==Pharmacology==
NM-2201 acts as a [[full agonist]] with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 0.332nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and 0.732nM at [[Cannabinoid receptor type 2|CB<sub>2</sub>]] [[cannabinoid]] receptors.<ref>{{cite journal|first1=Cornelius|last1=Hess|first2=ClaraT.|last2=Schoeder|first3=Thanigaimalai|last3=Pillaiyar|first4=Burkhard|last4=Madea|title=Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice|journal=Forensic Toxicology|date=1 July 2016|issn=1860-8965|pages=329–343|volume=34|issue=2|doi=10.1007/s11419-016-0320-2|first5=ChristaE.|last5=Müller|pmid=27429655|pmc=4929166}}</ref> It has been linked to serious adverse events in users.<ref>Samra K, Boon IS, Packer G, Jacob S. Lethal high: acute disseminated encephalomyelitis (ADEM) triggered by toxic effect of synthetic cannabinoid black mamba. ''BMJ Case Rep''. 2017 Apr 22;2017. pii: bcr-2016-218431. doi: 10.1136/bcr-2016-218431. {{PMID|28433979}}</ref>

==Legal status==
NM-2201 is specifically banned in Sweden,<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | publisher=Folkhälsomyndigheten | accessdate=9 July 2015 | language=Swedish}}</ref>  Germany ([[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]])<ref>{{Cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Gesetz über den Verkehr mit Betäubungsmitteln Anlage II|last=|first=|date=|website=www.gesetze-im-internet.de|publisher=Bundesministerium der Justiz und für Verbraucherschutz|language=German|access-date=24 October 2016}}</ref> and Japan,<ref>Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA. In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). ''Forensic Toxicol''. 2017 Jan;35(1):20-32. doi: 10.1007/s11419-016-0326-9. {{PMID|28286577}}</ref> but is also controlled in many other jurisdictions under [[structural scheduling of synthetic cannabinoids|analogue laws]].

==See also==
* [[EAM-2201]]
* [[MAM-2201]]
* [[THJ-2201]]
* [[SDB-005]]

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Cannabinoids]]
[[Category:Naphthoylindoles]]
[[Category:Organofluorides]]
[[Category:Designer drugs]]


{{cannabinoid-stub}}